Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The findings of the Women's Health Initiative (WHI) estrogen plus progestin (E+P) trial led to a substantial reduction in use of combined hormone therapy (cHT) among postmenopausal women in the United States. The economic effect of this shift has not been evaluated relative to the trial's $260 million cost (2012 U.S. dollars). OBJECTIVE: To estimate the economic return from the WHI E+P trial. DESIGN: Decision model to simulate health outcomes for a "WHI scenario" with observed cHT use and a "no-WHI scenario" with cHT use extrapolated from the pretrial period. DATA SOURCES: Primary analyses of WHI outcomes, peer-reviewed literature, and government sources. TARGET POPULATION: Postmenopausal women in the United States, aged 50 to 79 years, who did not have a hysterectomy. TIME HORIZON: 2003 to 2012. PERSPECTIVE: Payer. INTERVENTION: Combined hormone therapy. OUTCOME MEASURES: Disease incidence, expenditure, quality-adjusted life-years, and net economic return. RESULTS OF BASE-CASE ANALYSIS: The WHI scenario resulted in 4.3 million fewer cHT users, 126,000 fewer breast cancer cases, 76,000 fewer cardiovascular disease cases, 263,000 more fractures, 145,000 more quality-adjusted life-years, and expenditure savings of $35.2 billion. The corresponding net economic return of the trial was $37.1 billion ($140 per dollar invested in the trial) at a willingness-to-pay level of $100,000 per quality-adjusted life-year. RESULTS OF SENSITIVITY ANALYSIS: The 95% CI for the net economic return of the trial was $23.1 to $51.2 billion. LIMITATION: No evaluation of indirect costs or outcomes beyond 2012. CONCLUSION: The WHI E+P trial made high-value use of public funds with a substantial return on investment. These results can contribute to discussions about the role of public funding for large, prospective trials with high potential for public health effects. PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650
Self-citationState-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
Siebert, U., Alagoz, O., Bayoumi, A. M., Jahn, B., Owens, D. K., Cohen, D. J., & Kuntz, K. M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.014 · Cited by 588
The Relation between Funding by the National Institutes of Health and the Burden of Disease
Gross, C. P., Anderson, G. F., & Powe, N. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402406 · Cited by 509
Self-citationExpected Value of Sample Information Calculations in Medical Decision Modeling
Ades, A. E., Lu, G., & Claxton, K. (2004) · Medical Decision Making · doi:10.1177/0272989x04263162 · Cited by 364
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3
Siebert, U., Alagoz, O., Bayoumi, A. M., Jahn, B., Owens, D. K., Cohen, D. J., & Kuntz, K. M. (2012) · Medical Decision Making · doi:10.1177/0272989x12455463 · Cited by 348
Cited by
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
Rodgers, K. M., Udesky, J. O., Rudel, R. A., & Brody, J. G. (2018) · Environmental Research · doi:10.1016/j.envres.2017.08.045 · Cited by 443
Likelihood of Null Effects of Large NHLBI Clinical Trials Has Increased over Time
Kaplan, R. M., & Irvin, V. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132382 · Cited by 356
“The economic analysis estimated that there was about $140 returned for each dollar invested in the study[13].”
BackgroundRisk determination and prevention of breast cancer
Howell, A., Anderson, A. S., Clarke, R. B., Duffy, S. W., Evans, D. G., Garcia-Closas, M., Gescher, A. J., Key, T. J., Saxton, J. M., & Harvie, M. N. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0446-2 · Cited by 327
Making gender diversity work for scientific discovery and innovation
Nielsen, M. W., Bloch, C. W., & Schiebinger, L. (2018) · Nature Human Behaviour · doi:10.1038/s41562-018-0433-1 · Cited by 259
Metadata
- Authors
- Roth, J. A., Etzioni, R., Waters, T. M., Pettinger, M., Rossouw, J. E., Anderson, G. L., Chlebowski, R. T., Manson, J. E., Hlatky, M., Johnson, K. C., & Ramsey, S. D.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2014-05-06
- Volume
- 160
- Issue
- 9
- Pages
- 594-602
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2036396804
- Cited by
- 58
- References
- 5
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study. https://app.cochat.ai/papers/10.7326/m13-2348
- The paper
- Roth, J. A., Etzioni, R., Waters, T. M., Pettinger, M., Rossouw, J. E., Anderson, G. L., Chlebowski, R. T., Manson, J. E., Hlatky, M., Johnson, K. C., & Ramsey, S. D. (2014). Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study. Annals of Internal Medicine. https://doi.org/10.7326/m13-2348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.